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PROCDIM is a valuable tool to capture several patients reported outcomes and data
for chronic disease management. Such tools could be used for collecting data for
disease management, clinical trial and for observational studies for various
chronic diseases.
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VALIDATING AN ALTERNATIVE WEIGHTING ALGORITHM OF THE CHARLSON
COMORBIDITY INDEX (CCI) FOR RISK ADJUSTMENT IN PREVIOUSLY
HOSPITALIZED PATIENTS
Cheng LI, Rascati KL
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To validate an alternative weighting algorithm of the Charlson Co-
morbidity Index (CCI) for the prediction of health care expenditures and utilization
in previously hospitalized patients.METHODS:Data from the Medical Expenditure
Panel Survey (MEPS) Panel 12 (2007-2008) were retrieved for this retrospective co-
hort study. Two CCI scores were calculated for patients who were hospitalized in
2007: one based on the original weights (Charlson-CCI) and the other based on the
weights updated by Quan et al. (Quan-CCI) [both were developed to predict mor-
tality]. Adjusted R2 from linear regression models were used to estimate log-trans-
formed healthcare expenditures (COST) in 2008. Odds ratios and c statistics from
logistic regression models were used to compare the predictive power of the risk of
hospitalizations ( 1 admission), risk of emergency department visits ( 1 visit),
and high expenditures ( 90th percentile of COST) in 2008. RESULTS: Seven hun-
dred patients who had been previously hospitalized were included in the study.
The mean (SD) age was 52.5 (15.3) years, and 65% were female. In the linear regres-
sions, the Charlson-CCI explained more variance in COST than the Quan-CCI (ad-
justed R2  20.7% vs. 19.9%), adjusting for age and sex. The Charlson-CCI was a
better predictor of the risk of emergency department visits (c0.600) than the
Quan-CCI (c0.571). Compared with the Quan-CCI, the Charlson-CCI showed bet-
ter discriminatory power for the prediction of high-expenditure individuals
(c0.770 vs. 0.743) and the risk of hospitalizations (c0.589 vs. 0.581). The Quan-CCI
did not significantly predict high-expenditure individuals (OR1.15; 95% CI0.99-
1.33) or the risk of hospitalizations (OR1.14; 95% CI0.99-1.30). CONCLUSIONS: In
a group of previously hospitalized patients, the original CCI exhibited better dis-
crimination for the prediction of healthcare expenditures, hospitalizations, and
emergency department visits. The weights updated by Quan et al. were developed
to predict mortality and may have limited utility in predicting health care utiliza-
tion.
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USING PROBABALISTIC SENSITIVITY ANALYSIS IN BUDGET IMPACT MODELS
TO REDUCE UNCERTAINTY AND IMPROVE DECISION-MAKING
Latif F, Roberts G
Double Helix Consulting, London, UK
OBJECTIVES: Budget impact analysis (BIA) is formally required by many national
HTA regulatory agencies including NICE and the PBAC, in the UK and Australia,
respectively. Current practice only involves the use of point estimates to serve as
“best guess” for decision-makers. However, using probabilistic sensitivity analysis
(PSA) can serve to reduce parameter uncertainty in order to generate discussion
and ultimately improve decision-making. METHODS: Using the same techniques
applied to cost-effectiveness analysis, a PSA was incorporated into a budget impact
model used for a client’s medical device. This involved creating and running a
Monte-Carlo simulation (MCS) over 10,000 iterations to generate a 95% confidence
interval (CI) around the overall budget impact in addition to a probability curve.
RESULTS: Point-estimate budget impact was found to be a saving of £4,736,893
based on a number of pre-defined input parameters in the model. Running a MCS
generated a 95% CI: a saving of £10,367,403 and an incremental cost of £861,166
either side of the point-estimate. In addition, a probability curve was generated
with overall budget impact on the x-axis and probability on the y-axis. 25 data
points were generated running from a maximum potential saving of approxi-
mately £12m (1% probability) to an incremental cost of approximately £3m (100%
probability). CONCLUSIONS: Using PSA in this budget impact model demonstrates
that there is a significant likelihood this medical device could actually generate an
incremental cost rather than saving (which the point-estimate shows). This serves
as an example of how using this technique could serve to generate discussion
among decision-makers in order to make more informed and improved budget
impact decisions in the future.
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COULD CORPORATE SOCIAL RESPONSIBILITY PREDICT PHARMACEUTICAL
CORPORATE FINANCIAL PERFORMANCE?
Auamnoy T, Areepium N
Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: 1) To quantify CSR concept by developing a pharmaceutical compa-
nies namely Auamnoy’s visual analogue scales—a 24 measurement indicators in 6
dimensions to make a composite variate; 2) To perform a retrospective research to
explore relationship between CSR activities and corporate financial performance
(CFP); and 3) To discover prediction model to predict pharmaceutical CFP by CSR.
METHODS: Challenging literature reviews were executed on and on to find the
valid and reliable scales to measure CSR. Twelve appropriate CFP indicators were
discussed and then selected to evaluate 43 pharmaceutical companies perfor-
mance. The  value was set at 0.05, one side using SPSS version 17.0 to calculate all
statistical analysis. RESULTS: The six dimensions Auamnoy’s scales were Drug
development, Patients, Environment and safety, Social issues, Philanthropy and
Business ethics and – yielded acceptable Cronbach’s alpha 0.7415, 0.7154, 0.7151,
0.7426, 0.7217 and 0.7466 respectively. Pearson’s product moment correlation con-
firmed that CSR showed a significant positive correlated with (ROI, Sales, EPS, DPS,
BV, %Sales Growth, %ROA and %ROI) (r0.832, 0.489, 0.789, 0.631, 0.351,
0.298,0.455,0.336, p0.000, 0.000, 0.000, 0.000, 0.011, 0.030, 0.001, 0.008 respec-
tively). Finally, Regression analysis estimated significant seven models of pharma-
ceutical CFP–ROI, Sales, EPS, DPS, BV, %ROA and %ROI by CSR. CONCLUSIONS: The
answer was yes, pharmaceutical CSR could predict CFP. The more the pharmaceu-
tical companies invested in CSR. the more CFP they obtained.
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WHAT GUIDANCE IS AVAILABLE FOR BUDGET IMPACT ANALYSIS?
Kusel J1, Costello S2
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Ltd, Cambridge, UK
OBJECTIVES: There is a wealth of literature and guidance available for cost-effec-
tiveness research, but the guidance available on budget impact analysis (BIA) is less
familiar to many investigators. In times of increased budget constraint, however,
the importance and popularity of BIA is growing. The objective of this review was to
assess whether guidance on BIA methodology is available and consistent.
METHODS: Online searches were performed to identify published guidelines or
recommendations on BIA from any country. The guidelines were then reviewed for
whether they gave advice on certain pre-determined methodological categories.
RESULTS: National guidelines have been produced in Canada, Ireland, Scotland
and Poland specifically on how BIA in each of these countries should be performed.
Other countries such as the UK, Italy and Hungary include recommendations on
BIA within guidelines on health care economic assessment, but their focus is
largely on cost-effectiveness analysis. The national guidelines were consistent in
whether they made recommendations on perspective and time horizon, but varied
in whether they gave advice on market share determination, sources of costs,
inclusion of treatment of adverse events and the presentation of resource use and
costs separately. The definition of the term ‘incremental BIA’ was also used incon-
sistently. An ISPOR Task Force has produced international guidance for budget
impact methodologies, which is designed to support national guidelines rather
than supersede them and also to improve consistency across BIAs developed for
different settings. CONCLUSIONS: Several national and international bodies have
developed guidelines or tools for developing and reporting budget impact models.
However, different specifications exist and not all methodological aspects are
made explicit in every case. Consensus guidelines such as those produced by the
ISPOR task force are required to shape future national BIA recommendations.
PRM10
TO GET THE RIGHT PRICE – A DECISION SUPPORT METHOD TO OPTIMIZE
MANAGERIAL DECISIONS ON PUBLIC FUNDING PRICE TO APPLY FOR
Wilk NM1, Kloc K2
1Arcana Institute, Krakow, Malopolskie, Poland, 2Arcana Institute, Krakow, malopolskie, Poland
OBJECTIVES: In challenging economic times public funding decision makers are
getting tougher, so the managers have to be smarter to choose the right price and
optimally justify it. The objective is to present our method which rationally sup-
ports managerial decisions on pricing in public funding. METHODS: The decision
support method consists of the following steps: 1) identify all arguments relevant
to different price levels – e.g. based on prices of similar drugs that were accepted by
public payer or related to prices of the drug in other countries; 2) calculate maxi-
mum price that may be justified with each piece of an argument; 3) sort arguments
in price ascending order; 4) rank arguments in a pairwise manner against their
impact on probability of public funding acceptance using 5-point Likert scale; 5)
plot all arguments on a graph with price level on X axis and cumulative impact on
probability of acceptance on Y axis; and 6) calculate first derivative to identify local
maxima. The seventh step is the manager’s decision on choosing the right price
from the subset of local maxima. Local maxima represent the price levels for which
a relatively large increase in price associates with a relatively small decrease in
acceptance for public funding. RESULTS: The decision support analysis results in a
subset of price levels that the manager is recommended to choose the right price
from. The final choice may depend on acceptance/avoidance of risk or necessity to
achieve a specific turnover. All arguments that justify the chosen and higher prices
may be used to justify this price to public funding decision makers.CONCLUSIONS:
To ensure a pricing success to their companies and their own career development
Market Access managers should use the presented decision support method to
make possibly best informed choices concerning official prices of their drugs.
PRM11
LEARNING EFFECT IN ECONOMIC EVALUATIONS OF HEALTH CARE
INTERVENTIONS
Chang S, Sungher D, Diamantopoulos A
Symmetron Limited, Elstree, Herts, UK
OBJECTIVES:The presence of the learning effect has an impact on the effectiveness
of health technologies and so, it is relevant to capture this in an economic analysis.
The aim of this study is to explore the bibliography of learning curves in health care
economic evaluations. METHODS: In order to understand the bibliography of
learning curves in economic evaluations, a systematic review was conducted to
identify economic analyses that include a formal description of a learning effect.
The following databases were searched: Medline, Medline (R), Embase, EconLIT,
HEED and NHS EED. For a study to be included in the review, it had to be an
economic evaluation defined as a cost, utility or cost-effectiveness study. In addi-
tion, the study also had to formally analyse the learning effect by using statistical
analysis, graphs or tables. All non-human and non-English studies were also ex-
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cluded from the review. The studies included were categorised based on criteria
such as type of study, statistical methods for the learning effect, mathematical
framework for the economic analysis, year of publication, country and
intervention. RESULTS: The database search produced 930 articles. Only 2% of the
studies obtained were included given the above criteria. Of the excluded studies,
70% were excluded as they were not economic evaluations and 23% were excluded
as they did not formally present the learning effect. The remaining 7% were ex-
cluded based on other reasons: duplicates, non-English, non-human. The majority
of the studies are published after 2000. Of the included studies, the majority pre-
sented a learning effect related to health care costs. Two percent of the included
studies referred to utilities. Only one study synthesised cost and utilities.
CONCLUSIONS: Although the learning effect can have a notable impact on the
effectiveness of health care interventions, the economic evaluation literature on
the subject is very limited.
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AN APPLICATION OF A PROPOSED FRAMEWORK FOR FORMULARY LISTING IN
LOW-INCOME COUNTRIES: CASE OF CÔTE D’IVOIRE
Diaby V1, Lachaine J2
1University of Montreal, Île de Montréal, QC, Canada, 2University of Montreal, Montreal, QC,
Canada
OBJECTIVES: The Mutuelle Générale des Fonctionnaires et Agents de l’État de Côte
d’Ivoire (MUGEFCI) is a health mutual providing coverage services for its enrolees
(medical consultations, lab tests, medication expenses). This organization aims at
improving its current drug reimbursement process because of budgetary con-
straints. This study, therefore, aims at evaluating the feasibility of developing a
new formulary for the MUGEFCI in Côte d’Ivoire, by implementing a formulary-
listing framework specifically designed for under researched settings. METHODS:
The application of this framework, based on Multi-criteria Decision Analysis
(MCDA), consisted in four steps. First of all, we identified and weighted relevant
formulary listing criteria with their levels of variation. Then, we determined a set of
priority diagnostic/treatments to be assessed. Furthermore, scores were assigned
to these treatments according to their performance on the formulary listing criteria
levels. Last, we constructed a composite league table to rank the set of treatments
by priority order of reimbursement. A budget impact analysis was also conducted
to appraise the economic implications of the new composite drugs league table.
RESULTS: Policymakers in Côte d’Ivoire consider targeting cost-effectiveness and
severity of diseases as the most significant criteria for priority reimbursement of
drugs. This translates into a general preference for antimalarial, treatments for
asthma and antibiotics for urinary infection. Moreover, the results of the BIA sug-
gest that the new priority list of reimbursable drugs will be affordable when the real
economic impact of drugs per patient is under 66 US dollars. Over this threshold,
the MUGEFCI will have to select the reimbursable drugs according to their rank in
the priority list along with their respective budget impact per patient (cost per
patient). CONCLUSIONS: It is feasible to use MCDA to establish a formulary for
low-income countries. The application of this method is a step forward to trans-
parency in policymaking.
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ASSESSING THE METHODS FOR SYSTEMATIC REVIEWS OF ECONOMIC
EVALUATIONS
Paone S1, Di Tanna GL2, Corio M1, Jefferson T1, Cerbo M1, Migliore A1
1Agenas, Agenzia nazionale per i servizi sanitari regionali, Rome, Italy, 2Sapienza University of
Rome, Rome, Italy
OBJECTIVES: Robust and explicit methods to conduct systematic reviews of eco-
nomic evaluations are required to guarantee quality of reviews and their findings.
This is especially needed when assessing high resource-consuming topics such as
those related to the introduction of new imaging technologies. Our aim is to anal-
yse the methods for systematic reviews of economic evaluations of health
technologies. METHODS: We carried out a systematic review of methods for sys-
tematic reviews of economic evaluations by reading relevant parts of HTA meth-
odological manuals (“manuals”) and HTA reports from UK (“reports”) in English and
Italian at September 2010. RESULTS: We identified 27 manuals and 53 potential
reports. Among them, 6 and 40 contained relevant information respectively. None
of the 6 manuals described the criteria used for the identification or formulation of
the methods, or gave guidance on which method to follow. Among the 40 reports
included, 38/40 (95%) reports described search strategy and data bases used to
identify studies and inclusion criteria were presented in 21/40 (53%) reports. The
reports did not use a study quality assessment instrument were 9/40 (22.5%) while
20 different instruments were identified in the remaining reports. No report carried
out a quantitative synthesis of the data from the systematic review and 9/40 re-
ports (22.5%) clearly stated this. The reports that appear to include the data selec-
tively in their economic evaluation were 13/40 (32.5%). CONCLUSIONS: The ab-
sence of clear methodological guidance in manuals is reflected in the reports.
These show unclear rationale, methods and use of data from systematic reviews of
economic evaluations.
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MONDRIAAN: A DUTCH ’POPULATION’ LABORATORY
Klungel O
Utrecht University, Utrecht, The Netherlands
OBJECTIVES: Many excellent health care databases are available in The Nether-
lands for (pharmaco-)epidemiologic research. However, in isolation these data re-
main scattered and have limitations with regard to sample sizes and/or detail of
the registered information.The objective of Mondriaan is to optimize access to en
linkage of routine health care databases in the The Netherlands for (pharmaco-
)epidemiologic research.METHODS:We have built an ICT infrastructure for collec-
tion and linkage of healthcare/research data in The Netherlands. To protect pri-
vacy, pseudonimisation and linkage is performed by a trusted third party (TTP). A
data catalogue on subject level has been developed to allow queries within the
integrated databases to support designing (pharmaco-) epidemiologic studies (incl.
sample size calculations, assessment of completeness of data). RESULTS: We are
able to routinely link all pharmacy records from the National Foundation of Phar-
maceutical Statistics (SFK) (n14,000,000) on a patient base to several routine
health care databases such as the Almere Health Care database (n200,000), the
Julius GP Network (n200,000), and the AGIS claims database (n1,200,000). Cur-
rently we are integrating several other databases in the The Netherlands.
CONCLUSIONS: The project will deliver a large-scale, high-quality data platform
for innovative (pharmaco-)epidemiologic research.
PRM15
THE OUTCOME OF ISPOR EUROPEAN AND INTERNATIONAL CONGRESSES
BETWEEN 2005-2009
Boncz I1, Sebestyen A2, Kriszbacher I1
1University of Pécs, Pécs, Hungary, 2Baranya County Health Insurance Fund, Pécs, Hungary
OBJECTIVES: Many of the former socialist countries of Central and Eastern Europe
(CCEE) joined to the European Union in 2004. The aim of this study is to analyse to
outcome of ISPOR European and international congresses between 2005-2009 with
a special respect to the activity of CCEE. METHODS: We analysed the abstracts
presented at the ISPOR European or International cogresses and published in the
Value in Health journal between 2005-2009. We performed a database analysis of
value in Health journal on the Web of Science (Thomson Reuters) electronic data-
base of scientific publications. Three indicators were selected: author’s country,
institution (university) and name. RESULTS: The top-10 most active countries were
(abstract/1 million population): Switzerland (48.3), Wales (31.0), Sweden (26.2),
Denmark (25.3), Belgium (25.0), The Netherlands (23.0), England (19.3), Canada
(18.3), Scotland (16.0) and Hungary (14.7). Furthermore Slovakia (8.2) was ranked
16th, Czech Republic (5.0) 24th, Poland (4.1) 26th and Serbia (3.3) 29th. The top-10
most active universities were (number of abstracts): Univ So Calif (140), Univ To-
ronto (107), Univ Washington (100), Ohio State Univ (98), Erasmus Univ & MC (94),
Univ Maryland (93), Univ Pécs Hungary (93), Univ York (92), Harvard Univ (89) and
McMaster Univ (76). Three more CCEE university were ranked: Med Univ Warsaw
from Poland (38), Corvinus Univ Budapest from Hungary (30) and Comenius Univ
from Slovakia (27). The most active 10 authors were (number of abstracts): Boncz, I
(Hungary, 96), Taieb, C (France, 83), Balkrishnan, R (USA, Ohio, 77), Sebestyén, A
(Hungary, 71), Valentine, WJ (Switzerland, 65), Mantovani, LG (Italy, 60), Caro, JJ
(USA, MA, 57), Annemans, L (Belgium, 54), Kriszbahcer, I (Hungary, 52), Rejas, J
(Spain, 50). CONCLUSIONS: Former socialist countries of Central and Eastern Eu-
rope (CCEE) showed a significant activity at ISPOR European and International con-
gresses.
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COVARIANCE STRUCTURES FOR MODELING LONGITUDINAL DATA
Purdy C
AHRM Incorporated, Buffalo, NY, USA
OBJECTIVES: The objective of this analysis is to compare several covariance struc-
tures which are used in the modeling of longitudinal data. METHODS: A PUBMED
search reveals is a steady increase in prospective observational studies over the
past five years. Repeated measures models are frequently used to analyze longitu-
dinal data. For the purpose of these comparisons, a series of longitudinal datasets
are simulated. In order to facilitate comparisons with applications to longitudinal
datasets involving utilities; the dependent variable in the simulation datasets is a
continuous variable restricted to the support interval [0, 1]. The predictor variables
include a set of categorical and continuous variables, including a time varying
covariate. Datasets with four different types of time dependence were compared
(no time trend, log time trend, linear trend, exponential trend). Models with the
following covariance structures were evaluated: compound symmetry, unstruc-
tured, autoregressive, heterogeneous autoregressive, variance components and
toeplitz. Model comparisons were based upon Akaike information criteria (AIC)
and the Bayesian information criteria (BIC). RESULTS: The preferred covariance
structures for the dataset without a time trend were heterogeneous autoregressive
(AIC) and unstructured (BIC). The preferred covariance structure for the log trend
dataset was unstructured (AIC and BIC). The preferred covariance structures for the
linear trend dataset were variance components (AIC) and heterogeneous autore-
gressive (BIC). The preferred covariance structure for the exponential trend dataset
was variance components (AIC and BIC). CONCLUSIONS: The unstructured cova-
riance matrix is often the default choice for the covariance matrix for longitudinal
models. This model has the least number of assumptions and allows for the mod-
eling of each patient individually. However, the unstructured covariance structure
requires the most degrees of freedom and in some cases the estimated covariance
matrix does not converge. In these cases, covariance structures such as variance
components and heterogeneous autoregressive may present attractive options.
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SUITABILITY OF CLAD-CQR MODELS FOR OBTAINING QALYS
Cunillera O1, Vilagut G1, Medina A2, Tresserra R2, Alonso J1, Brugulat P2, García C1,
Ferrer M3
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